Charles River Laboratories Interna
$290.19Change from previous close: +1.17%Absolute change: +$3.36
At a glance
- Revenue growth
- −0.85%
- 2025 vs 2024
- Net margin
- -3.6%
- 2024: 0.3%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 4,015 | 4,050 | 4,129 | 3,976 |
| Cost of revenue | 2,692 | 2,718 | 2,627 | 2,513 |
| Gross profit | 1,323 | 1,332 | 1,503 | 1,463 |
| Selling, general and administrative | 743 | 751 | 748 | 665 |
| Operating income | 401 | 442 | 617 | 651 |
| EBIT | 7.5 | 219 | 718 | 682 |
| EBITDA | 411 | 581 | 1,032 | 986 |
| Interest expense | 107 | 126 | 137 | 59.3 |
| Pre-tax income | -99.5 | 93.1 | 581 | 623 |
| Income tax | 42.7 | 67.8 | 101 | 130 |
| Net income | -144 | 10.3 | 475 | 486 |
| Net income to common shareholders | -144 | 10.3 | 475 | 486 |
| Basic EPS | -2.91 | 0.20 | 9.27 | 9.57 |
| Diluted EPS | -2.91 | 0.20 | 9.22 | 9.48 |
| Average shares (basic) | 49.6 | 51.4 | 51.2 | 50.8 |
| Average shares (diluted) | 49.6 | 51.6 | 51.5 | 51.3 |